| Literature DB >> 31774672 |
Wen Zhang, Vitaliy M Sviripa, Liliia M Kril, Tianxin Yu, Yanqi Xie, W Brad Hubbard, Patrick G Sullivan, Xi Chen, Chang-Guo Zhan, Yang Yang-Hartwich1, B Mark Evers, Brett T Spear, Roberto Gedaly, David S Watt, Chunming Liu.
Abstract
The importance of upregulated Wnt signaling in colorectal cancers led to efforts to develop inhibitors that target β-catenin in this pathway. We now report that several "Wnt inhibitors" that allegedly target β-catenin actually function as mitochondrial proton uncouplers that independently activate AMPK and concomitantly inhibit Wnt signaling. As expected for a process in which mitochondrial uncoupling diminishes ATP production, a mitochondrial proton uncoupler, FCCP, and a glucose metabolic inhibitor, 2-DG, activated AMPK and inhibited Wnt signaling. Also consistent with these findings, a well-known "Wnt inhibitor", FH535, functioned as a proton uncoupler, and in support of this finding, the N-methylated analog, 2,5-dichloro-N-methyl-N-(2-methyl-4-nitrophenyl)benzenesulfonamide (FH535-M), was inactive as an uncoupler and Wnt inhibitor. Apart from suggesting an opportunity to develop dual Wnt inhibitors and AMPK activators, these findings provide a cautionary tale that claims for Wnt inhibition alone require scrutiny as possible mitochondrial proton uncouplers or inhibitors of the electron transport chain.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31774672 PMCID: PMC7560992 DOI: 10.1021/acs.jmedchem.9b01685
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446